Skip to main content
Annals of Intensive Care
Fig. 3 | Annals of Intensive Care

Fig. 3

From: Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Fig. 3

Mortality (upper panel A) and cure at TOC (bottom panel B) by SOFA component score (ITT population). Treatment differences were calculated as unstratified Newcombe 95% CIs; positive differences are in favor of ceftolozane/tazobactam, negative differences are in favor of meropenem. Participants whose 28-day mortality outcome was missing or unknown were analyzed as deceased. Participants with clinical failure at the EOT visit were counted as failures at the TOC visit. CI confidence interval, CV-SOFA cardiovascular, EOT end-of-therapy, R-SOFA respiratory SOFA component score, SOFA Sequential Organ Failure Assessment, TOC test-of-cure

Back to article page